Cargando…
In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
High-throughput sequencing describes multiple alterations in individual tumors, but their functional relevance is often unclear. Clinic-close, individualized molecular model systems are required for functional validation and to identify therapeutic targets of high significance for each patient. Here...
Autores principales: | Carlet, Michela, Völse, Kerstin, Vergalli, Jenny, Becker, Martin, Herold, Tobias, Arner, Anja, Senft, Daniela, Jurinovic, Vindi, Liu, Wen-Hsin, Gao, Yuqiao, Dill, Veronika, Fehse, Boris, Baldus, Claudia D., Bastian, Lorenz, Lenk, Lennart, Schewe, Denis M., Bagnoli, Johannes W., Vick, Binje, Schmid, Jan Philipp, Wilhelm, Alexander, Marschalek, Rolf, Jost, Philipp J., Miething, Cornelius, Riecken, Kristoffer, Schmidt-Supprian, Marc, Binder, Vera, Jeremias, Irmela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476619/ https://www.ncbi.nlm.nih.gov/pubmed/34580292 http://dx.doi.org/10.1038/s41467-021-25963-z |
Ejemplares similares
-
Adverse stem cell clones within a single patient’s tumor predict clinical outcome in AML patients
por: Zeller, Christina, et al.
Publicado: (2022) -
Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice
por: Ebinger, Sarah, et al.
Publicado: (2020) -
X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
por: Carlet, Michela, et al.
Publicado: (2022) -
A reporter system for enriching CRISPR/Cas9 knockout cells in technically challenging settings like patient models
por: Liu, Wen-Hsin, et al.
Publicado: (2021) -
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
por: Bahrami, Ehsan, et al.
Publicado: (2023)